By URL
By Username
By MRSS
Enter a URL of an MRSS feed
 
or

Onyx Pharmaceuticals is close to selling itself to larger rival Amgen after the cancer drugmaker's high stock price discouraged other companies from making a counter offer, according to three people familiar with the matter. Terms of an agreement have yet to be finalized, but the companies are negotiating a price of $130 per share, or nearly $9.5 billion.